Dov Bergwerk - Oct 13, 2023 Form 3 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Acting Chief Legal Officer
Signature
/s/ Dov Bergwerk
Stock symbol
TEVA
Transactions as of
Oct 13, 2023
Transactions value $
$0
Form type
3
Date filed
10/18/2023, 07:15 AM
Next filing
Nov 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TEVA Ordinary Shares 90.3K Oct 13, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TEVA Restricted Share Units Oct 13, 2023 Ordinary Shares 6.65K Direct F1, F2, F3
holding TEVA Restricted Share Units Oct 13, 2023 Ordinary Shares 14.6K Direct F1, F3, F4
holding TEVA Restricted Share Units Oct 13, 2023 Ordinary Shares 32K Direct F1, F3, F5
holding TEVA Restricted Share Units Oct 13, 2023 Ordinary Shares 31.1K Direct F1, F3, F6
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 7.5K $48.76 Direct F1, F7
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 12.8K $60.21 Direct F1, F8
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 12.8K $53.50 Direct F1, F9
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 17.5K $34.70 Direct F1, F10
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 8.76K $28.98 Direct F1, F11
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 27.5K $19.16 Direct F1, F12
holding TEVA Stock Options (right to buy) Oct 13, 2023 Ordinary Shares 7.01K $16.99 Direct F1, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Restricted share units were granted on February 28, 2020, with 6,653 vesting on February 28, 2024.
F3 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F4 Restricted share units were granted on March 5, 2021, with 7,293 vesting on March 5, 2024 and 7,294 vesting on March 5, 2025.
F5 Restricted share units were granted on March 4, 2022, with 10,678 vesting on each of March 4, 2024 and March 4, 2025 and 10,680 vesting on March 4, 2026.
F6 Restricted share units were granted on March 3, 2023, with 7,768 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026 and 7,771 vesting on March 3, 2027.
F7 Stock options were granted on March 12, 2014, with 2,500 having vested on each of March 12, 2015 and March 12, 2016 and 2,501 having vested on March 12, 2017.
F8 Stock options were granted on March 12, 2015, with 3,188 having vested on each of March 12, 2016, March 12, 2017 and March 12, 2018 and 3,189 having vested on March 12, 2019.
F9 Stock options were granted on March 17, 2016, with 3,188 having vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 3,190 having vested on March 17, 2020.
F10 Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 4,377 having vested on March 3, 2021.
F11 Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020 and 2,191 having vested on May 24, 2021.
F12 Stock options were granted on March 2, 2018, with 6,875 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 6,876 having vested on March 2, 2022.
F13 Restricted share units were granted on September 18, 2017, with 3,505 having vested on each of September 18, 2018 September 18, 2019.